Strive, Inc. (ASST), based in Dallas, describes itself as the first publicly traded asset management Bitcoin treasury company, focused on increasing Bitcoin per share over the long run. Its analyst price target set is small but uniformly bullish. Five current targets were reviewed: Maxim Group at $37 (October 2026), B. Riley Securities at $33 (September 2026), TD Cowen at $44 (September 2026), StoneX at $32 (June 2026), and H.C. Wainwright at $38 (May 2026).
These five figures average $36.80, rounded to a $37 central target, within a $32-to-$44 range. The wide spread reflects genuine disagreement about how to value a company whose results are dominated by Bitcoin's price rather than conventional earnings. TD Cowen's higher target and recent raises across the group have followed Strive's moves to broaden investor demand, including daily dividends on its perpetual preferred "SATA" shares, which analysts have framed as a capital-efficiency tool to accelerate Bitcoin accumulation per share. Even the lowest target sits modestly above the current price, a sign of optimism rather than caution across coverage. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
ASST closed at $28.97 on its most recent session, with a 52-week range of roughly $7.02 to $36.20 that underscores how volatile the shares have been. Reaching $37 requires a gain of about 28%, a substantial move rather than a marginal step. The path is heavily dependent on Bitcoin. Because Strive's balance sheet and income statement are marked to the cryptocurrency's price, the stock forecast effectively follows Bitcoin's trajectory, amplified by leverage and preferred-share issuance. The company reported only about $8.5 million in trailing revenue and a large net loss driven by mark-to-market swings, so traditional valuation metrics provide limited guidance.
The stock's prior 52-week high near $36.20 sits just below the $37 target, making that zone a key resistance level. A close above it would mark a new multi-month high. On the downside, the $22-to-$24 area, where the shares found footing in mid-October, is a notable support level, with the round-number $30 level acting as near-term psychological resistance. These levels matter because the shares tend to trend with Bitcoin, and breakouts or breakdowns in either asset tend to reinforce the other.
Analyst targets generally reflect a research horizon of roughly 12 months, though the exact horizon can differ by firm and none of the five reports reviewed specifies a guaranteed timeframe. Investors should monitor Bitcoin's price closely, along with Strive's upcoming earnings (estimated around November 10), any updates to preferred-share issuance and Bitcoin-per-share metrics, analyst revisions, and broader risk appetite and interest-rate conditions that influence speculative assets. From what I see, this is important because Bitcoin remains the dominant driver here.
The $37 central target, an average of five analyst price targets, implies roughly a 28% advance from the latest close of $28.97. It is a plausible but far-from-guaranteed objective: the setup rests almost entirely on Bitcoin's trajectory, with analysts uniformly bullish but divided over valuation, as the $32-to-$44 range shows. Rising Bitcoin and accretive accumulation would support the move, while a crypto drawdown, dilution, or thin underlying earnings could keep the shares well short of the target. Investors should watch Bitcoin's price, the Bitcoin-per-share metric, and upcoming earnings for the clearest signal of which direction dominates next.
One tool I find useful when monitoring volatile names tied to Bitcoin is Tickeron's AI Daily Buy/Sell Signals. It applies artificial intelligence to scan thousands of stocks and ETFs, producing Buy, Sell, or Hold signals based on technical behavior and market shifts. For a ticker like ASST, the signals can help identify potential turning points more quickly than manual review alone, serving as a practical complement to fundamental analysis of the Bitcoin treasury strategy.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Expect a price pull-back in the near future.
The Moving Average Convergence Divergence Histogram (MACD) for ASST turned negative on September 22, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 24 similar instances when the indicator turned negative. In 24 of the 24 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ASST declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ASST's RSI Oscillator exited the oversold zone, 22 of 24 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The Momentum Indicator moved above the 0 level on October 21, 2026. You may want to consider a long position or call options on ASST as a result. In 57 of 63 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 90%.
Following a +20.40% 3-day Advance, the price is estimated to grow further. Considering data from situations where ASST advanced for three days, in 140 of 161 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.
ASST may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 61 of 78 cases where ASST Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 78%.
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. ASST’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 98 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.378) is normal, around the industry mean (2.409). P/E Ratio (-39.088) is within average values for comparable stocks, (-3.173). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.319). Dividend Yield (0.000) settles around the average of (0.271) among similar stocks. ASST's P/S Ratio (113.636) is very high in comparison to the industry average of (15.798).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ASST’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 82, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry InvestmentManagers